j j agrees 25bn guidant deal pharmaceutical giant johnson johnson has agreed to buy medical technology firm guidant for 25.4bn 13bn the move by johnson johnson has been widely expected and the firm will pay 76 for each guidant share 6 more than wednesday s closing pric a number of johnson johnson s products are facing patent expirations while the company is also battling fierce competition from generic product analysts said that the deal is aimed at offsetting johnson johnson s reliance on a slowing drug busines